Journal article
Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial
JD Kean, J Sarris, A Scholey, R Silberstein, LA Downey, C Stough
Psychopharmacology | SPRINGER | Published : 2017
Abstract
Introduction: This study investigated the effects of a marine oil extract (PCSO-524®) on inattention, hyperactivity, mood and cognition in children and adolescents. PCSO-524® is a standardised lipid extract of the New Zealand green-lipped mussel and is an inflammatory modulator that inhibits the 5′-lipoxygenase and cyclooxygenase pathways and decreases concentrations of the pro-inflammatory arachidonic acid (AA). Methods: PCSO-524® or a matched placebo was administered for 14 weeks to 144 participants (123 males/21 females; mean age 8.7 years) with high hyperactivity and inattention in a randomised, double-blind, placebo-controlled study. The primary outcome was the Conners Parent Rating Sca..
View full abstractGrants
Funding Acknowledgements
Thanks are extended to Dr. David White and Dr. David A. Camfield for assistance with the study. Dr. Jerome Sarris is funded by a CR Roper fellowship.